Status:
COMPLETED
A Single-arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain After Selected Surgeries
Lead Sponsor:
Vertex Pharmaceuticals Incorporated
Conditions:
Acute Pain
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to evaluate the effectiveness, safety, and tolerability of SUZ for acute pain after laparoscopic procedures of the intraperitoneal or retroperitoneal cavities or arthrosco...
Eligibility Criteria
Inclusion
- Key
- Body mass index (BMI) of greater than or equal to (≥) 18.0 to less than or equal to (≤) 40.0 kilogram per meter square (kg/m\^2)
- Scheduled to undergo a procedure that is in one of the following categories that would typically be treated with opioid therapy for at least 72 hours postoperatively such as
- Laparoscopic intraperitoneal or retroperitoneal procedure
- Arthroscopic orthopedic procedure
- Key
Exclusion
- Participated in previous study with Suzetrigine or received Journavx
- Other protocol defined Inclusion/Exclusion criteria will apply.
Key Trial Info
Start Date :
March 27 2025
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 10 2025
Estimated Enrollment :
47 Patients enrolled
Trial Details
Trial ID
NCT06887959
Start Date
March 27 2025
End Date
November 10 2025
Last Update
December 15 2025
Active Locations (17)
Enter a location and click search to find clinical trials sorted by distance.
1
Scottsdale Clinical Trials
Scottsdale, Arizona, United States, 85260
2
Woodland International Research Group
Little Rock, Arkansas, United States, 72211
3
Gulfcoast Research Institute
Sarasota, Florida, United States, 34232
4
MedStar
Baltimore, Maryland, United States, 21218